To solve bioavailability and other drug delivery challenges
Portuguese active pharmaceutical ingredients and intermediates manufacturer Hovione has expanded its services to solve issues of poor bioavailability, patient acceptability and enable optimal delivery for non-oral routes of drug administration.
Building on the experience of more than 100 projects and successful commercialisation of spray dried dispersions Hovione’s solutions now include crystal design, particle size reduction to the micro or nano-scale and amorphous solid dispersions. These services are offered from bench to commercial scale and are complemented with formulation development and clinical manufacture to Phase II.
‘We are very pleased to offer our customers these technologies. In response to their needs, Hovione is investing in new technologies, many of them capable of handling highly potent compounds. These will help drive compounds with development challenges from early clinical to market,’ said Guy Villax, Hovione’s chief executive.
Hovione will be presenting its new service during the AAPS Annual Meeting and Exposition at McCormick Place, Chicago, US. The firm will also be exhibiting at Booth 3D39 at CPhI in Feria de Madrid, Spain (October 9-11).